Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,599 public trials 548 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Active, Not Recruiting

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06223516

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Arizona /ID# 260799 Phoenix, Arizona, United States
  • Mayo Clinic Hospital Jacksonville /ID# 262808 Jacksonville, Florida, United States
  • Sylvester Comprehensive Cancer Center /ID# 260798 Miami, Florida, United States
  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 261050 Ann Arbor, Michigan, United States
View all 15 locations
View Trial Details
Active, Not Recruiting

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

NCT04756726

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +20 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • University of California-San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute (Sarah Cannon Research Institute) Denver, Colorado, United States
  • Mayo Clinic Jacksonville, Florida, United States
View all 13 locations
View Trial Details
Active, Not Recruiting

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

NCT04268498

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Miami Miami, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Roswell Park Comprehensive Cancer Center Buffalo, New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Active, Not Recruiting

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Local Institution - 102 Scottsdale, Arizona, United States
  • Mayo Clinic Scottsdale, Arizona, United States
  • Local Institution - 107 Little Rock, Arkansas, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
View all 162 locations
View Trial Details
Active, Not Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Arkansas Little Rock, Arkansas, United States
  • City of Hope Duarte, California, United States
  • UC San Diego Health Moores Cancer Center San Diego, California, United States
  • University of California San Francisco (UCSF) San Francisco, California, United States
View all 106 locations
View Trial Details
Active, Not Recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

NCT06353022

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • CH de la Côte Basque Bayonne, France
  • CHU Caen Caen, France
  • CHRU DIjon Dijon, France
  • Chd Vendee La Roche-sur-Yon, France
View all 19 locations
View Trial Details

Related conditions